-
2010
8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...
-
Meet us
The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 1 compound in phase II, 3 compounds in phase I, and 2 compounds in pre-clinical development.
The development of Rotigaptide (ZP123, GAP-486) for arrhythmia (licensed to Wyeth) and of ZP120 for acute heart failure has been terminated after Phase II clinical trials. The development of ZP2435 for treatment of obesity was terminated in preclinical development.
The following table summarizes the status of Zealand Pharma's current product pipeline.
Product Candidate |
Indication |
Commercial Partner |
Status |
|
|
Completed enrollment of all Phase III studies by Q1, 2010 |
||
|
Combination of Lixisenatide/ZP10 |
|
Finalized Phase I by Q1, 2010 |
|
|
Post-surgical Organ Failure |
Action Pharma |
Phase II – initiated in 2008 |
|
|
Phase I – safety and tolerability study in colorectal patients initiated 2010 |
|||
|
Phase I - single dose safety and tolerability trial finalized 2009 |
|||
|
|
Phase I – single dose, safety and tolerability trial finalized Q3, 2010 |
||
|
|
Preclinical |
||
|
|
Preclinical |
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.
Home Legal Disclaimer Updated: 27.7.2010